Skip to main content

Advertisement

Table 3 Target Volume delineations and radiotherapy planning of GBM and AA

From: Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial

Radiotherapy Target volume Delineation Dose/fractionation Minimal dose coverage
CIRT boost GTV MET/FET PET or MRS abnormality, contrast enhancement, FLAIR abnormality representing residual tumor 3.00-6.00 GyE × 3 Fx 95%
PRT GTV MET/FET PET or MRS abnormality, contrast enhancement, FLAIR abnormality representing residual tumor N/A* N/A*
CTV60 GTV + 0.5 cm margin 2.00 GyE × 30 Fx 95%
CTV50 GTV + 1.5 cm margin 1.67 GyE × 30 Fx 95%
  1. GBM: glioblastoma, AA anaplastic astrocytoma, CIRT carbon ion radiotherapy, GTV gross tumor volume, MET/FET PET C-methionine/18F-fluoro-ethyl-tyrosine positron emission tomography, MRS magnetic resonance spectroscopy, FLAIR fluid-attenuated inversion recovery, N/A not applied, GyE gray-equivalents, Fx fraction, PRT proton radiotherapy, CTV60/50 clinical target volume receiving 60/50 GyE irradiation
  2. * N/A: Since the GTV of PRT is not a target volume to give prescription dose, so “N/A” is marked in these cells